BR0317523A - Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos - Google Patents

Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos

Info

Publication number
BR0317523A
BR0317523A BR0317523-5A BR0317523A BR0317523A BR 0317523 A BR0317523 A BR 0317523A BR 0317523 A BR0317523 A BR 0317523A BR 0317523 A BR0317523 A BR 0317523A
Authority
BR
Brazil
Prior art keywords
solution
preparation
ingredients
active
pharmaceutical formulations
Prior art date
Application number
BR0317523-5A
Other languages
English (en)
Inventor
Satish Pejaver
Navneet Puri
Poongunran Muthukumaran
Lalit Chordia
Original Assignee
Baxter Int
Thar Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Thar Technologies Inc filed Critical Baxter Int
Publication of BR0317523A publication Critical patent/BR0317523A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"PROCESSO PARA A PREPARAçãO DE FORMULAçõES FARMACêUTICAS DE COMBINAçãO UTILIZANDO FLUIDOS SUPERCRìTICOS". A invenção é direcionada a um processo para a preparação de uma formulação farmacêutica contendo dois ou mais ingredientes farmacêuticos ativos compreendendo: (a) contatar dois ou mais ingredientes farmacêuticos ativos com um fluido supercrítico para formar uma solução em fluido supercrítico; e (b) separar os ingredientes ativos da solução supercrítica para produzir um precipitado em pó. Preferivelmente, a formulação farmacêutica preparada de acordo com a invenção contém uma combinação de dois agentes antiinfecciosos ou dois agentes anticancerígenos. A invenção é direcionada adicionalmente a um processo para preparar uma formulação farmacêutica contendo dois ou mais ingredientes farmacêuticas ativos compreendendo: (a) combinar dois ou mais ingredientes farmacêuticas ativos com um cossolvente para formar uma solução; (b) contatar a solução com um fluido supercrítico; e (c) recuperar o precipitado numa forma de pó.
BR0317523-5A 2002-12-19 2003-12-19 Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos BR0317523A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43505402P 2002-12-19 2002-12-19
PCT/US2003/040608 WO2004056342A1 (en) 2002-12-19 2003-12-19 Process for preparing combination pharmaceutical formulations using supercritical fluids

Publications (1)

Publication Number Publication Date
BR0317523A true BR0317523A (pt) 2005-11-16

Family

ID=32682148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317523-5A BR0317523A (pt) 2002-12-19 2003-12-19 Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos

Country Status (9)

Country Link
US (2) US20040197412A1 (pt)
EP (1) EP1572156A1 (pt)
JP (1) JP2006516958A (pt)
CN (1) CN1726010A (pt)
AU (2) AU2003297391B2 (pt)
BR (1) BR0317523A (pt)
CA (1) CA2510019A1 (pt)
MX (1) MXPA05006528A (pt)
WO (2) WO2004056341A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107252A1 (en) * 2003-11-17 2005-05-19 Gaffney Anne M. Process for preparing mixed metal oxide catalyst
CN100336816C (zh) * 2005-12-14 2007-09-12 广州大学 一种舒巴坦制备方法
CN100464750C (zh) * 2006-02-23 2009-03-04 珠海联邦制药股份有限公司 一种制备含阿莫西林钠和克拉维酸钾的药物混合物的方法
WO2011016409A1 (ja) * 2009-08-05 2011-02-10 国立大学法人山口大学 アルコール化合物の製造方法
CN104224719A (zh) * 2013-06-06 2014-12-24 南京亿华药业有限公司 一种头孢地尼干混悬剂及其制备方法
WO2015053857A2 (en) * 2013-10-10 2015-04-16 New York University Efficient collection of nanoparticles
CN105030683B (zh) * 2015-07-06 2018-08-10 中国药科大学 一种超临界流体技术制备依托泊苷超细微粒的方法
CN106265542A (zh) * 2016-09-22 2017-01-04 北京化工大学 一种阿霉素纳米药物颗粒的制备方法
CN107714697B (zh) * 2017-11-08 2018-08-07 海南通用三洋药业有限公司 负载有替卡西林钠克拉维酸钾药物组合物的生物活性植骨材料及其制备方法
CN108409821A (zh) * 2018-03-19 2018-08-17 青岛国海生物制药有限公司 一种醋酸甲地孕酮纳米结晶的制备方法及醋酸甲地孕酮
CN111000732A (zh) * 2020-01-02 2020-04-14 上海创元化妆品有限公司 一种片状或热浇注产品的制备方法
CN111973613B (zh) * 2020-07-30 2022-04-08 瑞普（天津）生物药业有限公司 一种复方大观霉素粉针及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5757348A (en) * 1994-12-22 1998-05-26 Displaytech, Inc. Active matrix liquid crystal image generator with hybrid writing scheme
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US20030150085A1 (en) * 2002-02-08 2003-08-14 Lalit Chordia Manipulation of solvent properties for particle formation
US20030157031A1 (en) * 2002-02-08 2003-08-21 Lalit Chordia Method of and apparatus for forming and administering fine particles

Also Published As

Publication number Publication date
CN1726010A (zh) 2006-01-25
AU2003297391A1 (en) 2004-07-14
AU2003297391B2 (en) 2010-02-25
CA2510019A1 (en) 2004-07-08
WO2004056342A1 (en) 2004-07-08
JP2006516958A (ja) 2006-07-13
EP1572156A1 (en) 2005-09-14
MXPA05006528A (es) 2006-05-25
US20040202681A1 (en) 2004-10-14
WO2004056341A1 (en) 2004-07-08
AU2003297367A1 (en) 2004-07-14
US20040197412A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
JP6827092B2 (ja) ルリコナゾール含有外用医薬組成物
ES2539655T3 (es) Composición cosmética líquida que comprende un monoalcohol
BR0317523A (pt) Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
BR9814818A (pt) Métodos de tratamento de cápsulas e formulações farmacêuticas em pó secas
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
NO20064584L (no) Tetrahydropyridoindolderivater
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BR0307802A (pt) Formulações farmacêuticas de agentes antineoplásicos, em particular temozolomida, processos de produção e uso das mesmas
BR0214553A (pt) Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
PE20021017A1 (es) Composicion parenteral reconstituible
BR9901782A (pt) Forma para dosagem de nefazodona.
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
BR0109012A (pt) Composição farmacêutica, forma de dosagem unitária, solução oral, método para o tratamento da dor, e, método para o tratamento de inflamações
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
FR2756561B1 (fr) Composes heteroaryles, compositions pharmaceutiques et cosmetiques les contenant et utilisations
BR9916919A (pt) Compósito de sulfonamida e seu uso
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.